Join the NYIPLA for the upcoming Biologics & Biosimilars program on Wednesday, February 4th, at the offices of Orrick, Herrington & Sutcliffe LLP. The panelists for this year's event include:

• Larry Coury, Senior Vice President, Litigation and Dispute Resolution, Regeneron
• Mira Mulvaney, Associate VP - Assistant General Patent Counsel, IP Litigation, Eli Lilly & Company
• Angie Verrecchio, Assistant General Counsel, Patent Litigation, Johnson & Johnson
• Colman Ragan, VP, Chief Trademark Counsel & Head of U.S. IP Litigation, Teva Pharmaceuticals

Moderated by Irena Royzman (partner, Orrick, Herrington & Sutcliffe), the panelists will discuss the potential impact of the recent grant of certiorari in Amarin, pending IP regulatory/legislative proposals (including the RESTORE, ETHIC and the Skinny Label bills, the PTO's recent IPR NPRM, and the FDA's proposed new guidance on biosimilar comparative efficacy studies) on BPCIA litigation. The panelists will also provide an update on another hot topic for biologics and biosimilars – the IRA litigations that are currently pending (including BMS v. Kennedy; Novo Nordisk v. Kennedy, and Teva v. Kennedy).

Attendees will have the opportunity to earn up to 1.5 NY/NJ CLE Credit.